Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023-Reference-Cited by-同舟云学术

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023

Published:2021-11-18 Issue:1 Volume:113 Page:240-250
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Shoji Tadahiro¹^ORCID,Enomoto Takayuki²,Abe Masakazu³,Okamoto Aikou⁴,Nagasawa Takayuki¹,Oishi Tetsuro⁵,Nagase Satoru⁶,Mori Masahiko⁷,Inokuchi Yuki⁸,Kamiura Shoji⁹,Komiyama Shinichi¹⁰^ORCID,Takeshima Nobuhiro¹¹,Sugiyama Toru¹²

Affiliation:

1. Department of Obstetrics and Gynecology Iwate Medical University School of Medicine Iwate Japan

2. Department of Obstetrics and Gynecology Niigata University School of Medicine Niigata Japan

3. Department of Gynecology Shizuoka Cancer Center Shizuoka Japan

4. Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan

5. Department of Obstetrics and Gynecology Tottori University School of Medicine Tottori Japan

6. Department of Obstetrics and Gynecology Faculty of Medicine Yamagata University Yamagata Japan

7. Department of Gynecology Aichi Cancer Center Hospital Aichi Japan

8. Department of Biostatistics Kitasato Academic Research Organization Kitasato University Tokyo Japan

9. Department of Gynecologic Oncology Osaka International Cancer Institute Osaka Japan

10. Department of Obstetrics and Gynecology Faculty of Medicine Toho University Tokyo Japan

11. Department of Gynecology Cancer Institute Hospital Tokyo Japan

12. Department of Obstetrics and Gynecology St. Mary’s Hospital Fukuoka Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15185

Reference23 articles.

1. Cancer statistics, 2017

2. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

3. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

4. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study;International Journal of Gynecologic Cancer;2024-07-29

2. A disulfidptosis-related lncRNAs cluster to forecast the prognosis and immune landscapes of ovarian cancer;Frontiers in Genetics;2024-07-09

3. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer;Minerva Obstetrics and Gynecology;2024-06

4. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

5. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2024-02-28